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Ionizing radiation and many cancer drugs have the potential to produce germ-cell mutations that might lead to
genetic disease in the next generation. In a population-based study, we identiﬁed, from records in the Danish Cancer
Registry, 4,676 children treated for cancer. Their 6,441 siblings provided a comparison cohort. The results of a
search of the Central Population Register identiﬁed 2,630 live-born offspring of the survivors and 5,504 live-born
offspring of their siblings. The occurrence of abnormal karyotypes diagnosed in these offspring and also in any
pregnancies terminated following prenatal diagnosis of a chromosome abnormality was determined from the Danish
Cytogenetic Registry. After exclusion of hereditary cases and inclusion of the prenatal cases, after correction for
expected viability, the adjusted proportion of live-born children in survivor families with abnormal karyotypes (5.5/
2,631.5 [0.21%]) was the same as that among the comparison sibling families (11.8/5,505.8 [0.21%]). There were
no signiﬁcant differences in the occurrence of Down syndrome (relative risk ; 95% CI 0.16–5.47) or[RR]p 1.07
Turner syndrome ( ; 95% CI 0.17–7.96) among the children of cancer survivors, compared with theRRp 1.32
children of their siblings. These reassuring results are of importance to the survivors, to their families, and to genetic
counselors.
There are concerns about ill effects that cancer treatment
may have on children born to cancer survivors. Although
radiation and many cancer drugs produce somatic-cell
mutations, there is little information in humans on the
production of germ-cell mutations leading to genetic dis-
ease in the next generation. Adding to reassuring but scant
information (Boice et al. 2003), we evaluated cancer
treatment in Danish children and subsequent chromo-
somal aberrations in their offspring.
From the Danish Cancer Registry, 4,676 survivorswere
identiﬁed who were diagnosed with cancer at age !20
years between 1943 and 1996 and who survived until the
onset of fertility (age 15 years). Patients had to be alive
on or born after April 1, 1968, when the national Central
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Population Register (CPR) was established, with personal
identiﬁcation numbers for all citizens that permit linkage
among registers. A search of the CPR resulted in identi-
ﬁcation of 2,630 live-born offspring (50.6% boys) of the
survivors and 5,504 live-born offspring (52.3% boys) of
their 6,441 siblings (comparison cohort). The proportion
who were parents was lower among the survivors (30%;
1,381 parents) compared with their siblings (44%; 2,823
parents). The mean number of offspring per parent was
the same (1.9) for both survivors and siblings. All subjects,
including female partners of male survivors (Boice et al.
2003), were linked to the Danish Cytogenetic Registry,
which includes all normal and abnormal karyotypes di-
agnosed pre- or postnatally in Denmark since 1960, ex-
cluding stillbirths. All children with an abnormal karyo-
type were linked to the National Hospital Register, which
contains information for virtually every nonpsychiatric
hospital admission in Denmark since 1977, to learn
whether the child had been hospitalized for or with a
malformation. Information on radiotherapy (yes/no) was
obtained from the Danish Cancer Registry for the entire
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cohort and indicated that 37% of all cancer survivors
received radiation treatment. Information on chemother-
apy was abstracted from medical records only for sur-
vivors with affected offspring. For affected offspring and
fetuses of survivors, radiation doses to parental gonads
were estimated from details on medical records and from
experimental simulations by use of tissue-equivalent and
three-dimensional mathematical phantoms (Stovall et al.,
in press). Observed numbers of abnormal karyotypes in
the 4,676 families of cancer survivorswere comparedwith
numbers in the comparison cohort.
Of 4,676 survivors of childhood cancer, 8 had at least
one child or fetus with an abnormal karyotype (table 1
[individuals S1–S8]). In two affected families (of indi-
viduals S1 and S2), the abnormal karyotype is thought
to be hereditary. The remaining six chromosomal abnor-
malities were found in four offspring with Down syn-
drome (two diagnosed prenatally) and two with Turner
syndrome. It is noted that no cases of de novo structural
chromosomal abnormalities were observed in the fami-
lies with cancer survivors. Four of the eight survivors
with affected children had received neither radiotherapy
nor chemotherapy, and those who did undergo radio-
therapy received relatively low gonadal doses. Of the
6,441 control siblings, 19 had affected children or fe-
tuses (table 1 [individuals C1–C19). In six families, the
abnormal karyotype was inferred to be hereditary. The
offspring of these siblings were not registered in theHos-
pital Register as having a malformation. The three sub-
jects with fragile-X syndrome who were born to a con-
trol sibling, who was herself a fragile-X carrier, were not
included in the main analysis, which excluded hereditary
cases. Among the 13 families with affected children or
fetuses of nonhereditary origin, ﬁve subjects with Down
syndrome (one prenatal), four of Turner syndrome (one
prenatal and one a mosaic), and three subjects with Ed-
ward syndrome (two in one sibship, diagnosed prena-
tally) were recorded.
After exclusion of hereditary cases and adjustment of
the prenatally diagnosed and terminated cases for via-
bility (Hook et al. 1989; survival probabilities of 0.74
for Down, 0.35 for Turner, 0.36 for Edward), the ad-
justed proportion of live-born children with chromosome
abnormalities in survivor families was similar—(4 live
born 1.5 adjusted prenatal cases)/(2,630 live born
), or 0.21%—to the propor-1.5 adjusted prenatal cases
tion among the comparison sibling families—(10 live
born 1.8 adjusted prenatal cases)/(5,504 live born
), or 0.21%. Inclusion of the1.8 adjusted prenatal cases
hereditary cases also resulted in similar proportions in
the two cohorts; that is, 0.40% (10.5/2,631.5) and 0.36%
(19.8/5,505.8) among survivors and siblings, respec-
tively. These overall estimates were not adjusted for ma-
ternal age, but the median maternal age was similar in
the two cohorts; that is, 26 years (range 15–51 years)
among cancer survivors and 26 years (range 15–45
years) among siblings.
The adjusted live-born rates for Down syndromewere
compared with expectations based on the maternal age–
related rates of Cuckle et al. (1987). Both survivors and
siblings had similar numbers of offspring with Down syn-
drome, as expected; that is, 3.5 versus a maternal age–
adjusted expected number of 3.1 for the survivors and
4.7 versus 5.9 for the siblings. Both cohorts had similar
adjusted live-born rates for Turner syndrome, although
these were slightly higher than expected numbers, on the
basis of a rate of 1 in 2,500 live-born females (Jensen
1998); that is, 2 versus 0.5 and 3.4 versus 1.1 expected
among offspring of survivors and siblings, respectively.
All but one of the live-born subjects were diagnosed some
time after birth, which might explain the higher rates
than normally quoted for birth prevalence.
A direct comparison, conducted by calculations of
age-adjusted risk ratios, revealed an occurrence of Down
syndrome among live-born offspring born to survivors
comparable to that in offspring of siblings (relative risk
; 95% CI 0.16–5.47), whereas a slightly in-[RR]p 1.07
creased risk for Turner syndrome was observed in off-
spring of survivors ( ; 95% CI 0.17–7.96).RRp 1.32
In three of the four instances of Down syndrome re-
ported in the offspring of cancer survivors, the parent
affected with cancer was male, whereas it is evident that
most cases of nondisjunction leading to this syndrome
are maternal in origin (Jensen 1998). Similarly, the two
instances of Turner syndrome in the childhood-cancer
survivor group were born to female survivors, whereas
this nondisjunction most often is paternal in origin. It is
unfortunate that parent-of-origin studies for the nondis-
junction resulting in the children with Down and Turner
syndromes were not available, but it would seem un-
likely that any disturbance of sex-related nondisjunction
patterns had occurred in the survivors, since both Down
syndrome and Turner prevalence rates were similar to
those in the offspring of control siblings.
In this population-based study of 4,676 survivors of
childhood cancer, there was no indication of increased
risk of chromosomal abnormalities in their offspring. Al-
though we were able to evaluate chromosomal abnor-
malities diagnosed pre- or postnatally in the entire popu-
lation of Denmark since 1960, the relatively small num-
ber of affected children and fetuses and the fact that not
all of the cancer survivors received mutagenic treatment
precludes ﬁrm conclusions. However, our reassuring re-
sults accord with previous studies of survivors of child-
hood cancer (Byrne et al. 1998), including those using
other endpoints to measure heritable genetic conditions
such as congenital malformations (Boice et al. 2003),
and with the study of the children of the Japanese atomic
bomb survivors (UNSCEAR 2001). Because of the in-
creasing number of cancer survivors who are capable of
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having children, the issue of genetic disease in offspring
is of great importance to cancer survivors and their fami-
lies and to clinicians who provide genetic counseling.
Acknowledgments
This study was supported by the Danish Cancer Society, the
International Epidemiology Institute (IEI), and the Westlakes
Research Institute (agreement 01/12/99 DC). None of the fund-
ing sources had any involvement in the conduction of this study,
except for Dr. Boice, who is Scientiﬁc Director at IEI, and Dr.
Tawn, who is head of Genetics at Westlakes Research Institute.
We thank programmer Jan Hansen, Danish Cytogenetic Reg-
istry, for data extraction and introduction.
References
Boice JD Jr, Tawn EJ, Winther JF, Donaldson SS, Green DM,
Mertens AC, Mulvihill JJ, Olsen JH, Robison LL, Stovall M
(2003) Genetic effects of radiotherapy for childhood cancer.
Health Phys 85:65–80
Byrne J, Rasmussen SA, Steinhorn SC, Connelly RR, Myers
MH, Lynch CF, Flannery J, Austin DF, Holmes FF, Holmes
GE, Strong LC, Mulvihill JJ (1998) Genetic disease in off-
spring of long-term survivors of childhood and adolescent
cancer. Am J Hum Genet 62:45–52
Cuckle HS, Wald NJ, Thompson SG (1987) Estimating a
woman’s risk of having a pregnancy associated with Down’s
syndrome using her age and serum alpha-fetoprotein level.
Br J Obstet Gynaecol 94:387–402
Hook EB, Topol BB, Cross PK (1989) The natural history of
cytogenetically abnormal fetuses detected at midtrimester am-
niocentesis which are not terminated electively: new data and
estimates of the excess and relative risk of late fetal death
associated with 47, 21 and some other abnormal karyo-
types. Am J Hum Genet 45:855–861
Jensen PKA (1998) Kromosomafvigelser hos mennesket (Chro-
mosomal abberations in humans). Gads Forlag, Copenhagen
(in Danish)
Stovall M, Donaldson SS, Weathers RE, Robison LL, Mertens
AC, Winther JF, Olsen JH, Boice JD Jr. Genetic effects of
radiotherapy for childhood cancer: gonadal dose reconstruc-
tion. Int J Radiat Oncol Biol Phys (in press)
United Nations Scientiﬁc Committee on the Effects of Atomic
Radiation (UNSCEAR) (2001) Report to the General Assem-
bly, with scientiﬁc annexes: hereditary effects of radiation.
Report E.01.IX.2, United Nations, New York
